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DOI 10.1016/j.ccr.2012.02.028SUMMARYMCL1, which encodes the antiapoptotic protein MCL1, is among the most frequently amplified genes in
human cancer. A chemical genomic screen identified compounds, including anthracyclines, that decreased
MCL1 expression. Genomic profiling indicated that these compounds were global transcriptional repressors
that preferentially affectMCL1 due to its short mRNA half-life. Transcriptional repressors andMCL1 shRNAs
induced apoptosis in the same cancer cell lines and could be rescued by physiological levels of ectopicMCL1
expression. Repression of MCL1 released the proapoptotic protein BAK from MCL1, and Bak deficiency
conferred resistance to transcriptional repressors. A computational model, validated in vivo, indicated that
high BCL-xL expression confers resistance to MCL1 repression, thereby identifying a patient-selection
strategy for the clinical development of MCL1 inhibitors.INTRODUCTION
Inhibition of apoptosis is a critical step in the pathogenesis of
cancers, and is a major barrier to effective treatment (Adams
and Cory, 2007; Danial and Korsmeyer, 2004). It is now thought
that one or more components of the apoptosis pathway are
dysregulated in all cancers (Hanahan and Weinberg, 2011),
either by genetic mutation of the genes encoding these proteins
(e.g., point mutations, copy-number abnormalities, or chromo-
somal translocation) or by other mechanisms (e.g., epigenetic
mechanisms or upstream oncogenic mutations). Despite this
central importance in the development and maintenance of
cancer, few apoptosis-targeted therapeutics have reached
clinical evaluation.
Of particular importance is the BCL2 family of proteins.
Highly conserved from worm to human, these proteins controlSignificance
Human tumors effectively escape cell death by activating antia
We describe here a chemical genomic approach to the discov
BCL-xL expression as a primary resistancemechanism toMCL
show act at least in part through an MCL1-inhibitory mechanisthe activation of downstream caspases, which are the major
effectors of apoptosis. The BCL2 family can be divided into
three main subclasses, defined in part by the homology shared
within four conserved regions termed BCL2 homology (BH)
domains (Adams and Cory, 2007; Danial and Korsmeyer,
2004). The ‘‘multidomain’’ proapoptotic members BAX and
BAK possess BH1–BH3 domains, and together constitute
a requisite gateway to the intrinsic apoptosis pathway (Lindsten
et al., 2000; Wei et al., 2001). In contrast, the proapoptotic
proteins, such as BIM, PUMA, and NOXA, share homology
only within the BH3 amphipathic a-helical death domain,
prompting the title ‘‘BH3-only.’’ Antiapoptotic family members
such as BCL2, BCL-xL, and MCL1 show conservation in
all four BH domains. The BH1, BH2, and BH3 domains of
these proteins are in close proximity, and create a hydrophobic
pocket that can accommodate the BH3 domain of apoptotic mechanisms, one of which is amplification ofMCL1.
ery of repressors of MCL1 expression. We also identify high
1 inhibition, including resistance to anthracyclines, which we
m.
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et al., 2004).
Despite overwhelming genetic and functional evidence impli-
cating the BCL2-family proteins as therapeutic targets, effective
therapeutic inhibitors of these proteins have been difficult to
develop. Elegant NMR-based structural biology efforts led to
development of the small-molecule BCL2/BCL-xL inhibitor
ABT-737 (Oltersdorf et al., 2005) and its analog ABT-263, now
in early clinical trials (Tse et al., 2008). Although it is expected
that ABT-263 or related compounds will have clinical activity in
BCL2- or BCL-xL-dependent tumors, it is clear thatmany tumors
do not depend on these proteins but rather rely on other antia-
poptotic factors such as MCL1 (Lin et al., 2007; van Delft et al.,
2006).
MCL1 has only recently been recognized as an important
therapeutic target in cancer. MCL1 is highly expressed in
a variety of human cancers (Krajewska et al., 1996a, 1996b).
Its expression has been linked to tumor development (Zhou
et al., 2001) and resistance to anticancer therapies. For example,
overexpression of MCL1 is a major resistance mechanism for
the experimental BCL2/BCL-xL inhibitor ABT-737 (Chen et al.,
2007; Keuling et al., 2009; van Delft et al., 2006), and MCL1
has been similarly implicated in the resistance of non-BCL2-
family-targeted therapy (Wei et al., 2006). Importantly, we
recently reported that amplification of the MCL1 locus is one of
the most frequent somatic genetic events in human cancer,
further pointing to its centrality in the pathogenesis of malig-
nancy (Beroukhim et al., 2010). Although the development of
MCL1 inhibitors has been of considerable interest, no such
inhibitors have yet reached the clinic. A particularly promising
strategy, however, was recently reported by Walensky and
colleagues, whereby ‘‘stapled’’ helical MCL1BH3 peptides func-
tion as effective MCL1 inhibitors in preclinical models (Stewart
et al., 2010). Whether such stapled peptides will make for
effective clinical therapeutics remains to be established. Further-
more, no biomarkers for patient selection have been discovered
for MCL1 inhibitors. Therefore, we used a chemical genomic
strategy to identify MCL1-downregulating small molecules and
to discover biomarkers of MCL1 dependency.
RESULTS
Gene-Expression-Based High-Throughput Screen
Identifies Small Molecules Repressing MCL1
Expression
MCL1 is frequently amplified in human cancers (Beroukhim et al.,
2010), and is highly expressed across a panel of 729 human
cancer cell lines (see Figure S1A available online). We hypothe-
sized that it might be possible to discover small molecules that
decrease MCL1 expression, thereby activating the apoptosis
cascade in MCL1-dependent tumors. We therefore developed
an assay to profile the mRNA levels of MCL1 and 48 other
apoptosis-related genes using the Luminex bead-basedmethod
(Hieronymus et al., 2006; Peck et al., 2006) (Figure 1A; Table S1).
We profiled many apoptosis-related genes in addition to MCL1
in order to identify compounds that preferentially repress
MCL1 while preserving expression of the proapoptotic factors.
We carried out a pilot screen using MCF7 breast cancer cells
treated with 2,922 small-molecule compounds, including 530548 Cancer Cell 21, 547–562, April 17, 2012 ª2012 Elsevier Inc.FDA-approved drugs. We used MCF7 cells, which are deficient
in caspase-3, to avoid identifying compounds that repress
MCL1 expression through feedback apoptosis mechanisms.
We also performed the assay at an early time point (8 hr post-
treatment) for this reason. We counterscreened against
compounds that caused significant cell death at 8 hr using a
lactate dehydrogenase viability assay, reasoning that such
compounds must not be acting by classical apoptosis-inducing
mechanisms.
Twenty-four compounds (0.8%) decreased MCL1 expression
at least 2-fold (Figure 1B). All 24 compounds reduced MCL1
expression more than any of the other 48 apoptosis-related
genes assayed, suggesting at least some degree of preferential
activity against MCL1. We selected 14 commercially available
compounds for further testing. Seven of these exhibited sig-
nificant dose-related repression ofMCL1 expression. The seven
compounds included the natural product triptolide, the tran-
scription inhibitors 5,6-dichlorobenzimidazole riboside (DRB)
and actinomycin D, the kinase inhibitor 5-iodotubercidin, and
the anthracyclines doxorubicin, daunorubicin, and epirubicin.
Despite having distinct reported mechanisms of action (Table
S2), treatment with these compounds resulted in decreased
MCL1 expression in multiple cell lines, suggesting a com-
mon mechanism of MCL1 repression across cancer types
(Figure S1B).
Small Molecules that Repress MCL1 Share
Transcriptional Profiles
We compared genome-wide expression profiles of cells
following treatment with candidate compounds to determine
whether they shared a common mechanism of action. We
performed genome-wide gene-expression profiling in MCF7
cells following treatment with triptolide and actinomycin D. The
expression changes induced by triptolide and actinomycin D
were highly similar (R2 = 0.85), suggesting that, like actino-
mycin D, triptolide likely functions as a transcriptional inhibitor
(Figure 1C). Consistent with this observation, triptolide was
recently reported to bind to XPB, a subunit of TFIIH (Titov
et al., 2011), and inhibit phosphorylation of the C-terminal tail
of RNA polymerase II, which results in transcriptional inhibition
(Leuenroth and Crews, 2008).
Using the Connectivity Map database containing expression
profiles of 1,366 compounds (http://www.broadinstitute.org/
cmap) (Lamb et al., 2006), the triptolide-induced profile showed
a high degree of similarity to both doxorubicin and daunorubicin
(ranked 1 and 2 of 1,366, respectively, using Spearman correla-
tion) (Figure 1D). The anticancer effect of anthracyclines has
long been attributed to inhibition of DNA topoisomerase II
(Desmedt et al., 2011; Moretti et al., 2009). However, the DNA
topoisomerase II inhibitor etoposide induced a transcriptional
profile distinct from that induced by triptolide (Figure 1D). Taken
together, these results strongly suggest that the compounds
that emerged from our MCL1-repression screen, including the
anthracyclines, function as global transcriptional repressors.
We therefore refer to them as transcriptional repressor (TR)
compounds.
Strikingly, the TR compounds showed dramatic preferential
activity against MCL1 compared to the rest of the transcrip-
tome. For example, MCL1 was in the top 0.05 percentile of
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Figure 1. Bead-Based High-Throughput Gene-Expression Screening Identified MCL1 Repression by Transcriptional Inhibitor Compounds
(A) Illustration of screening procedure. mRNA levels of MCL1 and 48 other apoptotic genes were measured in MCF7 cells 8 hr after treatment with 2,922 small
molecules.
(B)MCL1 expression modulation by 2,922 compounds. Compounds and DMSO controls were sorted byMCL1 expression repression. The y axis displays log2
gene-expression fold change.
(C) Gene-expression profiling by Affymetrix microarrays of MCF7 cells with triptolide (500 nM) and actinomycin D (2.5 mM) for 4 hr. Both the x and y axes display
log2 gene-expression fold alteration.
(D) The 1,317 compounds used to treat MCF7 cells in the Connectivity Map are displayed in descending order of their correlation with triptolide (calculated as the
Spearman rank correlation of the differential gene expression across the Affymetrix U133A chip).
(E–G) Gene-expression repression by triptolide at 2 hr (E), 4 hr (F), and 6 hr (G). The genes are ranked by the extent of repression. The y axis displays log2
gene-expression fold alteration. Arrowheads indicate MCL1.
See also Figure S1 and Tables S1 and S2.
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Chemical Genomics Identifies MCL1 Biomarkertriptolide-repressed genes (Figures 1E–1G), and the MCL1
transcript was repressed more than 5-fold within 2 hr of
treatment (Figure 1E). On the contrary, none of the other
BCL2-family genes were repressed more than 2-fold. Consis-
tent with the reported short half-life of MCL1 protein (30 min)
(Adams and Cooper, 2007), inhibition of MCL1 mRNA caused
a rapid decrease in MCL1 protein levels that occurred prior
to poly(ADP ribose) polymerase (PARP) cleavage, a marker
for caspase activation (Figure S1C).TR Compounds Share a Pattern of Cell Killing and Can
Be Rescued by Physiologically Relevant Levels of MCL1
Based on the sharedmechanisms suggested above, we hypoth-
esized that if MCL1 repression is a biologically relevant target
of TR compounds, then these compounds should induce
apoptosis in the same cancer cell lines. We therefore measured
caspase activation and cell viability of 74 non-small-cell lung
cancer (NSCLC) and 33 breast cancer cell lines following
treatment with actinomycin D, doxorubicin, triptolide, and flavo-
piridol. Flavopiridol has previously been reported to repress
MCL1 expression via inhibition of CDK9 (Chen et al., 2005).
Responses to the TR compounds were highly correlated when
measured both by caspase activation and cell viability (Pearson
r > 0.82 and 0.93, respectively, when compared to triptolide)
(Figures 2A and 2B). As expected, cell viability was highly corre-
lated with caspase activation for each TR compound (Figure 2C;
Pearson r > 0.59), indicating that the TR compounds impair cell
viability via apoptosis. By contrast, compounds that kill cells
via different mechanisms, such as methotrexate and etoposide,
demonstrated different patterns of cytotoxicity (Figures 2A and
2B; Figure S2A). Despite the fact that TR compounds repress
the expression of many genes, ectopic expression of physiolog-
ical levels of MCL1 rescued cells from TR-compound treatment
(Figures 2D–2F). In contrast, ectopic expression ofMCL1 had no
such rescue effect for other classes of compounds, such as
methotrexate (Figures 2D–2F).
If TRs block global transcription, we hypothesized that combi-
nation treatment with TR compounds would counteract the
effects of compounds that kill cells by inducing the expression
of proapoptotic proteins. The proteasome inhibitor bortezomib
induces apoptosis through the induction of the proapoptotic
protein NOXA (Gomez-Bougie et al., 2007; Voortman et al.,
2007). As predicted, treatment with the TR compounds doxoru-
bicin, actinomycin D, or triptolide rescued cells from the
apoptotic effects of bortezomib, whereas treatment with the
non-TR compound etoposide had no effect (Figures S2B–S2F).
Similarly, the TR compounds were able to rescue cells fromFigure 2. TR Compounds Shared a Pattern of Cell Killing
(A and B) Seventy-four NSCLC (blue dots) and 33 breast cancer (red dots) cell line
with the effect of other compounds (y axis), measured both by cell viability after
Concentrations of the compounds for the displayed data were actinomycin D (1.
ABT-263 (6.25 mM), and triptolide (2.5 mM).
(C) Correlation between cell viability and caspase activation.
(D) Expression levels of endogenousMCL1 and FLAG-MCL1 in HMC-1-8 cells afte
each panel, cells were treated with the compound for 0, 2, 4, and 6 hr (left to rig
(E and F) Ectopic expression of physiological levels of FLAG-MCL1 rescued HMC
activation at 6 hr (E) and cell viability at 24 hr (F). Error bars indicate standard de
See also Figure S2.the histone deacetylase (HDAC) inhibitor vorinostat (Figure S2G),
which kills cells via the induction of the proapoptotic proteins
BMF and NOXA (Wiegmans et al., 2011).
MCL1 Knockdown Phenocopies TR Compounds
In order to determine whether MCL1 repression explains the
activity of TR compounds, we tested whether their effects could
be phenocopied by knockdown of MCL1. We treated 17 breast
cancer and 16 NSCLC cell lines representing different levels of
sensitivity to TR compounds with each of the five most effective
shRNAs selected from a library of 60 anti-MCL1 shRNAs (Fig-
ure 3A). The response to the five MCL1 shRNAs was highly
correlated (R2 > 0.64 for breast cell lines and R2 > 0.55 for
NSCLC cell lines) (Figure 3B). Ectopic expression of MCL1 with
a heterologous 30 UTR at physiologically relevant levels was
able to rescue cells from the two MCL1 shRNAs targeting the
30 UTR of MCL1 but not the three MCL1 shRNAs targeting the
coding region of MCL1 (Figure 3C), indicating that their cellular
effects are most likely due to MCL1 repression as opposed to
off-target effects.
In addition, we generated shRNAs against BCL-xL to test
whether MCL1-dependent cells were sensitive to knockdown
of other antiapoptotic genes. The responses to the five most
effective BCL-xL shRNAs (out of the 24 shRNAs tested) were
highly correlated (Figures 3D and 3E; Figure S3A), but these
responses did not correlate with the response to the MCL1
shRNAs (R2 = 0.002) (Figure 3F; Figure S3B).
Impaired viability induced by doxorubicin was strongly corre-
lated with the effects of MCL1 shRNAs [R2 = 0.80 for breast
cancer cells (Figure 3G) and R2 = 0.74 for NSCLC cells].
Conversely, doxorubicin sensitivity did not correlate with the
effects of shRNAs targeting BCL-xL (R2 = 0.0001 for breast
cancer cell lines) (Figure 3H). Furthermore, doxorubicin did not
induce additional significant cell death after MCL1 knockdown,
consistent with MCL1 repression being a major effector of
doxorubicin action (Figures 3I and 3J). Triptolide yielded similar
results, suggesting that this is a general property of TR
compounds (Figure S3C). Taken together, these results further
support the notion that a subset of tumor cells is dependent
upon MCL1 for survival, and that TR compounds act largely via
MCL1 repression.
Discovering Predictive Biomarkers ofMCL1 Essentiality
We next sought to discover biomarkers that are predictive of
MCL1 essentiality by comparing TR-compound sensitivities
with genomic data. Such biomarkers would prove useful for
the prediction of sensitivity to any present or future MCL1s were treated with small molecules. The effect of triptolide (x axis) is compared
24 hr of treatment (A) and fold-caspase-3 activation after 6 hr of treatment (B).
25 mM), doxorubicin (12.5 mM), flavopiridol (6.25 mM), methotrexate (6.25 mM),
r treatment with the indicated compounds were evaluated by western blot. For
ht for each compound).
-1-8 cells from TR compounds but not methotrexate, as measured by caspase
viation of duplicate measurements.
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Figure 3. MCL1 Knockdown Phenocopied TR Compounds
(A) Knockdown efficiency of the five best MCL1 shRNAs as determined by western blot.
(B) Effects of one shRNA (MCL1-8) on cell viability are plotted on the x axis against the effects of the other fourMCL1 shRNAs on the y axis. Data were measured
from 17 breast cancer cell lines.
(C) Effect of expressing physiological levels of FLAG-taggedMCL1 on apoptosis induced byMCL1 shRNAs targeting the 30 UTR ofMCL1 (MCL1-8 andMCL1-56)
or targeting the coding region ofMCL1 (MCL1-20,MCL1-48, andMCL1-50) in HMC-1-8 cells. Error bars indicate standard deviation of duplicate measurements.
(D) Five BCL-xL shRNAs effectively knocked down BCL-xL expression. H1437 and H23 cells had longer exposure time than HCC15 and SKLU1 cells for western
blots to show the shRNA effects.
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Chemical Genomics Identifies MCL1 Biomarkerinhibitors. We developed an analytical method to infer groups of
compounds that induce sensitivity in similar cancer genetic
subtypes and infer predictive biomarkers of sensitivity to each
compound group. Briefly, the method uses an expectation-
maximization algorithm and iterates until convergence between
clustering groups of compounds based on the similarity of their
response profiles, and uses an elastic net algorithm to infer
a predictive model for each group based on its genetic features
(Lee et al., 2009). The method further employs a bootstrapping
procedure to obtain a parsimonious model containing only
robustly predictive features (Figure 4A; see Supplemental Exper-
imental Procedures for details).
We examined the genetic features (copy number and expres-
sion data for >18,000 genes, and mutation data for 34 genes)
across 72 cell lines for which we had TR-compound sensitivity
measurements. To ensure that our predicted biomarkers were
specific to sensitivity induced by the TR compounds, we also
performed dose-response measurements on 37 additional
control compounds (Table S2). The algorithm identified a cluster
of compounds consisting of all of the TR compounds (actino-
mycin D, doxorubicin, flavopiridol, and triptolide), as well as
three additional compounds (puromycin, emetine, and anisomy-
cin) that function as global repressors of protein translation (Fig-
ure 4B). Similar to MCL1 mRNA, the extremely short half-life of
MCL1 protein likely explains the selective effects of protein
translation inhibitors on MCL1 activity.
The predictive model of sensitivity to the group of transcrip-
tional and translational repressors contained only a single
feature, corresponding to mRNA expression of BCL-xL. Specif-
ically, low expression of BCL-xL was associated with sensitivity,
and high expression of BCL-xL was associated with resistance
to compounds that repress MCL1 expression. The half-life of
BCL-xL protein is much longer than that of MCL1 (Figure S1C),
consistent with its ability to prevent apoptosis induced by
transcriptional and translational inhibitors. Also consistent with
this observation, sensitivity to MCL1 shRNAs anticorrelated
with BCL-xL mRNA levels in the 17 breast cancer cell lines
(R2 = 0.57) (Figure 4C).
We next sought to derive a computational model for the causal
interactions that explain how MCL1 and BCL-xL influence
sensitivity to TR compounds. We applied the ARACNE
reverse-engineering algorithm (Basso et al., 2005; Margolin
et al., 2006), which is designed to deconvolute direct and indirect
interactions among a set of covariates, and derived a network of
direct interactions among variables corresponding to gene
expression and copy number of MCL1 and BCL-xL and sensi-
tivity to TR compounds. We used as input to the algorithm
amatrix of values across the panel of 72 cell lines, corresponding
to normalized expression and copy number of MCL1 and
BCL-xL, as well as sensitivity to the TR compounds, computed
as the average of normalized IC50 values across all TR(E) Effects of one shRNA (BCL-xL-2) on cell viability are plotted on the x axis a
measured from 17 breast cancer cell lines.
(F–I) Effects of MCL1 shRNAs (G and I) or BCL-xL shRNAs (F and H) on cell viab
(G andH), orMCL1 shRNAs + doxorubicin (I) plotted on the y axis in 17 breast canc
xL for 3 days, or 2 days followed by treatment with 5 mM doxorubicin for an add
(J) Examples of cell lines that were resistant (T47D), partially sensitive (HCC1954
See also Figure S3.compounds. This approach yielded amodel in which expression
of BCL-xL was indeed the direct predictor of sensitivity to TRs
(Figure 4D). As expected, gene expression of BCL-xL and
MCL1was directly influenced by the copy number of the respec-
tive genes (Figures 4E and 4F). Interestingly, the model indicated
an epistatic relationship between MCL1 copy number and
BCL-xL expression. MCL1 copy number was negatively corre-
lated with BCL-xL expression (Figure 4G), suggesting that
MCL1 amplification may decrease the selective pressure
requiring BCL-xL for inhibition of apoptosis.
Sequestration of Proapoptotic Proteins by MCL1
and BCL-xL
The above data suggested that breast and lung cancer cells
with low expression of BCL-xL rely on MCL1 to sequester
proapoptotic proteins. Upon repression of MCL1 protein levels,
proapoptotic proteins might be released from MCL1 and cause
downstream caspase activation and apoptosis. BIM binds to
all antiapoptotic proteins (Me´rino et al., 2011). In a panel of
19 NSCLC cell lines, in cells expressing low levels of BCL-xL,
depletion of MCL1 by immunoprecipitation resulted in depleting
nearly the entirety of BIM (Figures 5A and 5B). In contrast, in
cells expressing high levels of BCL-xL, only a small fraction of
BIM was sequestered by MCL1 (Figures 5A and 5B). Further-
more, when BCL-xL was overexpressed in cells that normally
have low levels of BCL-xL, the fraction of BIM bound by MCL1
decreased significantly (Figure 5C). These experiments demon-
strate a shuttling of BIM sequestration between MCL1 and
BCL-xL, depending on their relative expression levels. To
explore whether the release of BIM from MCL1 explains the
apoptotic effect of MCL1-repressing TR compounds, we
repeated the MCL1-BIM coimmunoprecipitation experiments
under conditions of TR treatment. Surprisingly, despite the TR
compounds triptolide or flavopiridol significantly reducing
MCL1 levels, the majority of BIM protein remained bound to
the residual MCL1 (Figures S4A and S4B). In addition, BIM
knockdown by shRNA did not abrogate the sensitivity to TR
compounds (Figures S7C–S7G), although we cannot exclude
the possibility that more complete BIM knockdown might have
a more dramatic effect.
Because BIM seemed unlikely to be the principal proapoptotic
mediator of MCL1 repression, we considered other candidate
proteins. MCL1 coimmunoprecipitation experiments showed
that whereas the majority of PUMA, BAK, and BAX proteins
were not bound by MCL1 (Figure 5A; Figure S4A), significant
amounts of PUMA and BAK were pulled down by MCL1, and
overexpression of BCL-xL disrupted this interaction (Figures
5C and 5D). MCL1-bound PUMA decreased after triptolide-
mediated MCL1 repression, but this result is best explained
by triptolide’s concomitant repression of PUMA expression (Fig-
ure 5D). To test the possibility that BAK release from MCL1gainst the effects of the other four BCL-xL shRNAs on the y axis. Data were
ility plotted on the x axis against sensitivity to MCL1 shRNAs (F), doxorubicin
er cell lines. Cells were infectedwith viruses carrying shRNAs forMCL1 orBCL-
itional 24 hr (median of five MCL1 shRNAs or BCL-xL shRNAs, as indicated).
), or sensitive (HMC-1-8) to MCL1 inhibition. Dox, doxorubicin.
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Figure 4. Unbiased Computational Analysis Identified TR Compound Sensitivity Predicted by Low Expression of BCL-xL
(A) Schematic of biomarker discovery algorithm (see Supplemental Experimental Procedures for details).
(B) BCL-xL expression as a predictive biomarker of TR-compound sensitivity. The expectation-maximization algorithm identified one cluster that contained all
of the TR compounds (bottom panel; blue indicates drug sensitivity, red indicates resistance), coupled to a single predictive feature, BCL-xL RNA expression
(top panel; blue indicates low level of expression, red indicates high expression).
(C) Correlation between expression level ofBCL-xL (x axis) and cell viability uponMCL1 knockdown (y axis), represented as the percent viability relative to control
shRNAs, averaged over two replicates treated for 3 days with five different shRNA constructs targeting MCL1 across a panel of 17 breast cancer cell lines.
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Chemical Genomics Identifies MCL1 Biomarkerexplains the TR effect, we used Bak/ MEFs to determine
contribution of Bak in TR compound-induced apoptosis. Bak
deletion nearly completely rescued cells from TRs but did not
protect cells from the non-TR compound trichostatin A (Figures
5E–5H). BAX and BAK are bothmultidomain proapoptotic BCL2-
family proteins. However, BAK proved unique in that we did not
detect MCL1-BAX interaction in coimmunoprecipitation experi-
ments (Figures 5C and 5D), and Bax/ cells were not rescued
from TR compounds (Figures 5E–5G). Taken together, our data
suggest that MCL1 protects cells from cell death at least in
part through sequestration of BAK, and this sequestration is
diminished with TR compound-mediated MCL1 repression.
BCL-xL Predicts MCL1 Dependency In Vivo
An important question in developing biomarkers of MCL1
dependency is whether resistance mechanisms observed
in vitro hold in vivo, where tumor-microenvironment interactions
are known to modulate apoptotic mechanisms (Bewry et al.,
2008; Buggins et al., 2010). We therefore examined the in vivo
response of two NSCLC cell lines grown as xenografts in
NOD-SCID mice. H1437 cancer cells express low levels of
BCL-xL and are sensitive to triptolide (as a prototype MCL1
repressor) in vitro. HCC15 cells, in contrast, express high levels
of BCL-xL and are triptolide resistant in vitro. This pattern of
sensitivity persisted in vivo. Triptolide significantly attenuated
the growth of the H1437 NSCLC cancer model (Figures 6A and
6B). By contrast, in the HCC15 xenograft model, triptolide did
not significantly affect tumor volume or survival of the mice
(Figures 6C and 6D). Western blotting of whole-tumor lysates
demonstrated that treatment with triptolide decreased MCL1
protein abundance and increased PARP cleavage in the H1437
xenograft model (Figure 6E), indicating that triptolide repressed
MCL1 expression and induced apoptosis in vivo.
Our model predicts that patients with high levels of BCL-xL
expression are resistant to TRs. To test this hypothesis, we
investigated the relationship between BCL-xL gene expression
and clinical response to neoadjuvant treatment with the anthra-
cycline epirubicin in 114 estrogen receptor (ER)-negative breast
cancer patients for which it was determined whether a complete
pathological response (pCR) was achieved (Desmedt et al.,
2011). BCL-xL showed significant differential expression
between patients who achieved pCR and those who did not (Fig-
ure 6F). As previously reported, expression of topoisomerase 2A
(TOP2A) did not correlate with response to epirubicin (Figure S5),
consistent with our finding that anthracyclines kill tumor cells via
a transcriptional repressivemechanism rather than via a topoiso-
merase-inhibitory mechanism as has been generally assumed.
BCL-xL Is a Functional Determinant of MCL1
Dependency
We next investigated whether BCL-xL was simply a marker of
MCL1 dependency or whether it was a functional determinant(D) The ARACNE reverse-engineering algorithm was used to identify direct inte
expression and gene copy number. Arrows represent inferred direct interactions,
corresponding nodes. Arrows indicate the presumed direction of causality (e.g., c
red lines indicate negative correlations.
(E–G) Comparisons of gene expression and copy-number values of MCL1 and
expression. (F) BCL-xL copy number versus BCL-xL expression. (G) MCL1 copyof response. Overexpression of BCL-xL in MCL1-dependent
lines protected them from apoptosis induced by MCL1 shRNAs
or TR compounds (Figures 7A–7C) but not by other cytotoxic
agents such as methotrexate (Figures 7B and 7C), suggesting
a specific effect for TR compounds. Conversely, BCL-xL knock-
down conferred sensitivity in cell lines otherwise resistant to TR
compounds. Cell lines resistant to treatment with TR compounds
(using doxorubicin as a representative example) were sensitive
to combined treatment with BCL-xL shRNAs (Figures 7D and
7G), and cell lines resistant to treatment with MCL1 shRNAs
were sensitive to combined treatment with the BCL-xL inhibitor
ABT-263 (Figures 7E and 7G). The viability of cells treated with
BCL-xL shRNAs was highly correlated with viability after treat-
ment with the BCL-xL inhibitor ABT-263, and combined treat-
ment of cells with ABT-263 and BCL-xL shRNAs did not yield
synergistic effects (Figures 7F and 7G).
The above data suggest that TR compounds would exhibit
a synergistic effect when used in combination with BCL-xL inhib-
itors. We treated a panel of 74 NSCLC cell lines with a 42-point
dose-response matrix (six concentrations of triptolide or actino-
mycin D, and seven concentrations of ABT-263 or ABT-737). We
examined the synergy between TR compounds and BCL-xL
inhibitors for each cell line by computing the excess growth inhi-
bition over the Bliss independence model for each combination
of compound concentrations (Figures 8A–8C). Cell lines that
were highly sensitive to TR compounds showed no evidence of
synergy when treated in combination with ABT-737. Cell lines
that were resistant to TR compounds and to BCL-xL inhibitors
were sensitive to the combination (Figures 8A–8C).
A synergy score was computed for each combination experi-
ment in each of the 74 NSCLC cell lines by summing the excess
over Bliss independence across all dose combinations. The
synergy score was averaged over the four combination experi-
ments, performed by pairing triptolide or actinomycin D with
ABT-263 or ABT-737. This synergy score was highly correlated
with expression of BCL-xL (Figure 8D), suggesting that high
expression of BCL-xL determines the synergistic relationship
between TR compounds and BCL-xL-inhibitory compounds,
and that resistance to TR compounds, caused by high expres-
sion of BCL-xL, can be overcome by treating in combination
with BCL-xL inhibitors. Consistent with this notion, ABT-263
released BAK from BCL-xL (Figure 8E).
DISCUSSION
At an accelerating pace, the genomic characterization of human
cancer is elucidating the molecular basis of the disease. Recent
large-scale analyses of gene copy number in cancer demon-
strated that the genes encoding the BCL2-family proteins
MCL1 and BCL-xL are frequent targets of amplification. Low-
level MCL1 amplification is particularly notable, representing
one of the most common copy-number abnormalities in all ofractions between sensitivity to TR compounds and MCL1 and BCL-xL gene
with the weight of the edge proportional to the mutual information between the
opy number to gene expression). Black lines indicate positive correlations and
BCL-xL across 643 cancer cell lines. (E) MCL1 copy number versus MCL1
number versus BCL-xL expression.
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Figure 5. MCL1 Is the Major Antiapoptotic Protein in Cells with Low BCL-xL Expression
(A and B) Cell lysates of the indicated NSCLC cell lines were subjected to immunoprecipitation with an anti-MCL1 antibody (M), an anti-BCL-xL antibody (X), or no
antibody control (N). The indicated proteins left in the postimmunoprecipitation fraction were detected using western blotting (A). The fraction of unbound BIM
and BIM input was quantified by ImageJ software, and the color denotes cell viability after 24 hr of treatment with triptolide (B).
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Chemical Genomics Identifies MCL1 Biomarkerhuman cancer (Beroukhim et al., 2010). In support of a function-
ally important role of MCL1, numerous studies have elucidated
the critical role of MCL1 in preventing tumor cell death (Warr
and Shore, 2008).
Using a multiplexed Luminex bead-based assay, we screened
for compounds that reducedMCL1 expression while preserving
the expression of proapoptotic genes. Although the compounds
that emerged from this screen were general transcriptional
repressor compounds (as opposed to specifically targeting the
MCL1 locus), they preferentially repressed MCL1 because of
the short half-life of MCL1 mRNA and protein. Multiple lines of
evidence suggest that TR compounds induce apoptosis in
cancer cells primarily through repression of MCL1 expression,
including: (1) upon treatment with TR compounds, MCL1 protein
levels decreased rapidly and preceded caspase activation; (2)
ectopic expression of physiological levels of MCL1 rescued
cancer cells fromTRcompounds, despite the expression of other
genes still being repressed; (3) the pattern of TR-compound
sensitivity across a panel of cancer cell lines closely mirrored
the pattern of sensitivity of those cell lines to MCL1 knockdown
by RNAi; (4) of over 40,000 genomic features measured, the top
feature that predicted sensitivity to TR compounds was the low
expression of BCL-xL, which shares redundant function with
MCL1; (5) ectopic expression of BCL-xL rescued cancer cells
from TR compounds; (6) MCL1 repression by TR compounds
resulted in the release of proapoptotic protein BAK from MCL1;
and (7) Bak deficiency protected cells from TR compounds.
These results suggest that the mechanism of cell death induced
by TR compounds is best explained byMCL1 inhibition.
This indicated that some of the widely used chemotherapeutic
drugs such as anthracyclinesmay preferentially repressMCL1 to
induce apoptosis in tumor cells. Although the antitumor effect of
anthracyclines has long been speculated to be related to the
drug’s inhibition of DNA topoisomerase II (Desmedt et al.,
2011; Moretti et al., 2009) and an association between low
TOP2A expression and anthracycline response in ER-negative
breast cancer patients has been reported (Martin et al., 2011),
our data suggest that their activity may be largely explained by
inhibition of transcription, leading most dramatically to the
repression of short-lived MCL1 transcripts. Although it is
possible that multiple mechanisms of action explain the anti-
tumor effects of anthracyclines, at least in the experimental
cancer models studied here, anthracycline gene-expression
consequences most reflected transcriptional inhibition rather
than DNA topoisomerase II inhibition. Furthermore, the similar
pattern of sensitivity of cell lines toMCL1 knockdown compared
to anthracycline treatment is also consistent with an MCL1-
mediated transcriptional inhibitory effect. Last, our observation(C) HMC-1-8 cells stably expressing FLAG-BCL-xL via the MSCV retroviral vect
precipitation using an anti-MCL1 antibody. Input, unbound, and immunoprecipita
more concentrated than input and unbound.
(D) HMC-1-8 cells were treated with 2 mM triptolide for the indicated times and
agarose beads, eluted with an MCL1 peptide, and western blotted for proapop
unbound.
(E–H) Wild-type (WT), Bak/, Bax/, and Bax/;Bak/ MEFs were treated w
trichostatin A (H), at the indicated concentrations for 7 hr (E, for caspase activatio
measurements.
See also Figure S4.that BCL-xL expression is predictive of resistance to MCL1
repression both in model systems and in patients with breast
cancer further strengthens the anthracycline-MCL1 connection.
We note that the concentration of doxorubicin used in our
experiments approximates that observed in human tumor
tissues (1.9–24.4 mM) (Rossi et al., 1987). Doxorubicin stimulates
topoisomerase II-mediatedDNA cleavage only at low concentra-
tions, whereas at doses greater than 0.4 mM, topoisomerase
II-mediated DNA cleavage is lost (Tewey et al., 1984). These
data therefore suggest that at clinically relevant concentrations,
anthracyclines act as transcriptional repressors, as opposed to
DNA-damaging agents.
The transcriptional inhibitory role of anthracyclines is also of
importance when considering anthracycline-based combination
therapies. The transcriptional induction of proapoptotic proteins
has been reported to be crucial for the efficacy of many classes
of antineoplastic agents including radiation (Jeffers et al., 2003;
Villunger et al., 2003), the proteasome inhibitor bortezomib
(Gomez-Bougie et al., 2007; Voortman et al., 2007), the HDAC
inhibitor vorinostat (Wiegmans et al., 2011), and the kinase inhib-
itors imatinib (Kuroda et al., 2006) and erlotinib (Gong et al.,
2007). Anthracyclines may block the induction of such proapop-
totic proteins and counteract, rather than synergize with, those
therapies. For example, we found that doxorubicin treatment
actually rescues cancer cells from bortezomib- and vorinostat-
induced killing (Figure S2). Such antagonistic actions may be
preventable by adjusting the dosing schedule of combination
therapies, but the results serve as a reminder that knowledge
of mechanisms of action should ideally be considered in devel-
oping combination strategies.
Taken together, the results reported here elucidate a strategy
for the development of MCL1 inhibitors as cancer therapeutics.
The multiplexed, gene-expression-based high-throughput
screening approach described here holds promise for the future
discovery of specific inhibitors of MCL1 expression and for the
use of chemical genomic approaches to elucidate small-mole-
cule mechanisms of action. The study also highlights the power
of genomically characterized cell lines for the discovery of
predictive biomarkers of drug response. Most immediately, the
work suggests an approach to the clinical development of any
MCL1 inhibitor in breast and NSCLC tumors, focusing on tumors
expressing low levels of BCL-xL as a patient-selection strategy.EXPERIMENTAL PROCEDURES
Cell Culture, Caspase, and Viability Assay
All human cell lines were part of the Broad-Novartis Cancer Cell Line Ency-
clopedia Project (http://www.broadinstitute.org/ccle/home) or gifts fromor or the Lenti6.3 lentiviral vector, or LacZ control were subjected to immuno-
tion (IP) fractions were analyzed by western blotting. The IP fraction was 5-fold
subjected to immunoprecipitation with an anti-MCL1 antibody conjugated to
totic proteins. The IP fraction was 5-fold more concentrated than input and
ith TR compounds triptolide (E–F) or flavopiridol (G), or non-TR compound
n) or 24 hr (F–H, for viability). Error bars indicate standard deviation of duplicate
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Figure 6. Cells Expressing Low Levels of BCL-xL Were Sensitive to Triptolide In Vivo
(A–D) H1437 (lowBCL-xL expression; A and B) and HCC15 (highBCL-xL expression; C and D) NSCLC cell lines were grown as xenografts in NOD-SCIDmice, and
the mice were treated with triptolide or vehicle as indicated. (A and C) Tumor volume. (B and D) Survival curves. Error bars indicate standard deviation of tumor
volume of eight or nine mice.
(E) Triptolide treatment in vivo reduced MCL1 expression and induced PARP cleavage, a marker of apoptosis in tumors. Mice were treated either with vehicle
alone or triptolide for 7 weeks, or with vehicle for 7 weeks followed by 1 or 3 days of triptolide.
(F) Correlation between BCL-xL expression levels and resistance to epirubicin in ER-negative breast cancer patients (GEO accession number GSE16446). The
distribution of BCL-xL expression levels, averaged over all BCL-xL probe sets on the Affymetrix U133 Plus 2 array, is displayed as a box plot for patients who
obtained (n = 16, blue dots, right column) or did not obtain (n = 98, red dots, left column) pathological complete response to single-agent epirubicin treatment.
Whiskers of box plots represent 5%–95% data span. Box plots present median, 25th, and 75th percentiles of data.
See also Figure S5.
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MEFs were gifts from Anthony Letai at the Dana-Farber Cancer Institute.
Caspase activity was measured by the Caspase-Glo 3/7 kit and cell viability
was measured by CellTiter-Glo (both from Promega). cDNAs for ectopic558 Cancer Cell 21, 547–562, April 17, 2012 ª2012 Elsevier Inc.expression were from the Human ORFeome Collection by Mark Vidal at
the Dana-Farber Cancer Institute. Compounds were purchased from
commercial sources listed in Table S2 or were synthesized at the Broad
Institute.
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Figure 7. BCL-xL Expression Determined Sensitivity to TR Compounds and MCL1 Repression
(A) Effect of ectopic expression of BCL-xL on apoptosis induced by MCL1 shRNAs in HMC-1-8 cells. Error bars indicate standard deviation of duplicate
measurements.
(B and C) Ectopic expression of BCL-xL protected sensitive HMC-1-8 cells from TR compounds but not methotrexate, as measured both by caspase activity
(B) and cell viability (C). Error bars indicate standard deviation of duplicate measurements.
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Genes and Gene-Expression Profiling by Microarray
MCF7 cells growing in 384-well dishes were treated with 2,922 small mole-
cules from small-molecule libraries from the Broad Institute Chemical Biology
Program for 8 hr before being lysed. mRNA in cell lysates was hybridized to
dT20-conjugated plates (QIAGEN) and then reverse transcribed by Superscript
II (Promega). The resulting covalently attached cDNA was amplified by liga-
tion-mediated amplification. For each gene to be assayed, upstream and
downstream probes with unique barcode tags and universal primer sites
were annealed to targeted cDNA, and ligation by Taq DNA ligase (New
England BioLabs) generated a sequence complementary to the transcript.
The ligation product was PCR amplified using biotin-conjugated universal
primers. The PCR products were then captured by hybridization to probes
complementary to the barcodes that were linked to uniquely colored polysty-
rene beads (Luminex). The products were subsequently stained with strepta-
vidin-phycoerythrin (SAPE) (Invitrogen). Each gene product was identified
by the color of its capture bead and quantified using the associated SAPE
fluorescence, as measured by a Luminex detector. MCF-7 cells were treated
with 500 nM triptolide or 2.5 mM actinomycin D for 2, 4, or 6 hr, and gene
expression was profiled using Affymetrix microarrays (Gene Expression
Omnibus [GEO] accession number GSE28662).
RNAi and Ectopic Expression
shRNA viral infection was performed as previously described (Moffat et al.,
2006). The targeted sequences for the best shRNAs for MCL1 and BCL-xL
are listed in Supplemental Experimental Procedures. Cell viability following
treatment with MCL1 or BCL-xL shRNAs was compared to results using
three control shRNAs against luciferase or LacZ. For combination studies, cells
infected with lentivirus carrying shRNAs were selected with or without puro-
mycin (2.5 mg/ml) for 2 days before small molecules were added. Cell viability
was measured 24 hr after addition of small molecules. A FLAG tag was added
N-terminal of MCL1 or BCL-xL, and FLAG-MCL1 or FLAG-BCL-xL was cloned
into an Entry vector (Invitrogen) followed by recombination into a murine stem
cell virus (MSCV) destination vector. A BCL-xL Entry clone was also cloned
into the pLenti6.2 destination vector (Invitrogen) for Figures 7A–7C.
Western Blot and Coimmunoprecipitation
Cells in Figure 6A were lysed in cell lysis buffer (Cell Signaling Technology).
Otherwise, cells were lysed in CHAPS lysis buffer (50 mM Tris-Cl [pH 7.4],
150 mM NaCl, 1% CHAPS, 1 mM EDTA, 1 mM EGTA, protease inhibitors,
PhosSTOP [Roche], and 20 mM MG132). Protein lysates were incubated with
antibody for MCL1 (Santa Cruz Biotechnology) or BCL-xL (Cell Signaling
Technology) overnight, and then protein A/G Plus beads (Santa Cruz Biotech-
nology) were added and incubated for an additional 4 hr. Agarose beads
conjugated with an MCL1 antibody and an MCL1 peptide were used in
Figure 5D. Anti-FLAG beads and 3X FLAG peptides (both from Sigma) were
used in Figure 8E. Antibodies for MCL1 western blots were from Santa Cruz
Biotechnology and BD Pharmingen. BCL-xL, BIM, PUMA, BAK, and PARP
antibodies were from Cell Signaling Technology. BAX and ACTIN antibodies
were from Millipore. Protein quantification was performed with ImageJ (NIH).
Animal Studies
Mice were imaged 2 weeks after subcutaneous injection of H1437-Luc-
mCherry or HCC15-Luc-mCherry cells to identify mice with established tumor
burden. Tumormeasurements were taken twiceweekly to track tumor volume.
All mice had established tumors at 2 weeks and were entered into treatment
groups each containing eight or nine mice, with all groups having around the
same bioluminescent imaging average. Treatments were administered daily
via intraperitoneal injection and mice were measured weekly for 6 weeks.
The animals had tumor measurements taken twice weekly. The time to sacri-(D–F) The effects of BCL-xL shRNAs (D and F) orMCL1 shRNAs (E) on cell viability
(D and F) orMCL1 shRNAs (E) and doxorubicin (D) or ABT-263 (E and F) in 17 brea
or BCL-xL for 3 days, or 2 days followed by treatment with 5 mM doxorubicin or 1
shRNAs, as indicated).
(G) Examples of combination treatment of MCL1 or BCL-xL shRNAs and doxoru
See also Figure S5.
560 Cancer Cell 21, 547–562, April 17, 2012 ª2012 Elsevier Inc.fice was determined by tumor volume reaching 1,500 cm2 or tumor ulceration.
The xenograft mice were generated, housed, and bred in the Dana-Farber
Cancer Institute animal facility. All animal experiments were approved by the
Dana-Farber Cancer Institute Institutional Animal Care and Use Committee.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.ccr.2012.02.028.
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Figure 8. TR Compounds and BCL-xL Inhibitor Compounds Synergistically Killed Cells with High BCL-xL Expression
(A–C) Example of synergy calculation. Cell lines expressingBCL-xL at the lowest (NCI-H23; top panel) and highest (SKLU1; bottom panel) levels, across a panel of
74 NSCLC cell lines.
(A) Bliss independence model. Dose-response curves for single-agent treatment with ABT-263 and triptolide were used to compute the null-hypothesis surface
of expected response to combination treatment with ABT-263 and triptolide using a Bliss independence model. The x and y axes represent concentrations of
ABT-263 and triptolide in log10(nM), and the z axis (as well as the color scale) represents the expected percent growth inhibition for each combination of
compound concentrations under the null-hypothesis model.
(B) Dose-response matrix. Observed response surfaces for the combination experiments were plotted.
(C) Excess over Bliss independence. Excess percent growth inhibition over the null-hypothesis model was computed for each combination of compound
concentrations by subtracting the growth inhibition values displayed in (A) from those in (B). Black represents no excess growth inhibition and yellow represents
excess growth inhibition (scale 0–1).
(D) BCL-xL expression level versus compound synergy across the panel of 74 cell lines. The x axis displays the log2 expression level of BCL-xL. The y axis
displays the synergy score, computed by summing the excess over Bliss independence values (as shown in C) over all combinations of compound concen-
trations. The synergy scores displayed in the plot represent the average synergy score over the four combination experiments, performed by pairing triptolide or
actinomycin D with ABT-263 or ABT-737.
(E) Cells stably expressing FLAG-tagged BCL-xL were treated with ABT-263 at the indicated concentrations for 3 hr, subjected to immunoprecipitation with
anti-FLAG antibody beads, and eluted with 3X FLAG peptides. The IP fraction was 5-fold more concentrated than input and unbound.
Cancer Cell
Chemical Genomics Identifies MCL1 Biomarker
Cancer Cell 21, 547–562, April 17, 2012 ª2012 Elsevier Inc. 561
Cancer Cell
Chemical Genomics Identifies MCL1 BiomarkerDesmedt, C., Di Leo, A., de Azambuja, E., Larsimont, D., Haibe-Kains, B.,
Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P., Carly, B., et al. (2011).
Multifactorial approach to predicting resistance to anthracyclines. J. Clin.
Oncol. 29, 1578–1586.
Gomez-Bougie, P., Wuille`me-Toumi, S., Me´noret, E., Trichet, V., Robillard, N.,
Philippe, M., Bataille, R., and Amiot, M. (2007). Noxa up-regulation and Mcl-1
cleavage are associated to apoptosis induction by bortezomib in multiple
myeloma. Cancer Res. 67, 5418–5424.
Gong, Y., Somwar, R., Politi, K., Balak, M., Chmielecki, J., Jiang, X., and Pao,
W. (2007). Induction of BIM is essential for apoptosis triggered by EGFR kinase
inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4,
e294.
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next gener-
ation. Cell 144, 646–674.
Hieronymus, H., Lamb, J., Ross, K.N., Peng, X.P., Clement, C., Rodina, A.,
Nieto,M., Du, J., Stegmaier, K., Raj, S.M., et al. (2006). Gene expression signa-
ture-based chemical genomic prediction identifies a novel class of HSP90
pathway modulators. Cancer Cell 10, 321–330.
Jeffers, J.R., Parganas, E., Lee, Y., Yang, C., Wang, J., Brennan, J., MacLean,
K.H., Han, J., Chittenden, T., Ihle, J.N., et al. (2003). Puma is an essential medi-
ator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4,
321–328.
Keuling, A.M., Felton, K.E., Parker, A.A., Akbari, M., Andrew, S.E., and Tron,
V.A. (2009). RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis
in melanoma: role for a caspase-8-dependent pathway. PLoS One 4, e6651.
Krajewska, M., Fenoglio-Preiser, C.M., Krajewski, S., Song, K., Macdonald,
J.S., Stemmerman, G., and Reed, J.C. (1996a). Immunohistochemical analysis
of Bcl-2 family proteins in adenocarcinomas of the stomach. Am. J. Pathol.
149, 1449–1457.
Krajewska, M., Krajewski, S., Epstein, J.I., Shabaik, A., Sauvageot, J., Song,
K., Kitada, S., and Reed, J.C. (1996b). Immunohistochemical analysis of
bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol.
148, 1567–1576.
Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C.,
Kimura, S., Ottmann, O.G., Druker, B.J., Villunger, A., et al. (2006). Bim and
Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resis-
tance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci.
USA 103, 14907–14912.
Lamb, J., Crawford, E.D., Peck, D., Modell, J.W., Blat, I.C., Wrobel, M.J.,
Lerner, J., Brunet, J.P., Subramanian, A., Ross, K.N., et al. (2006). The
Connectivity Map: using gene-expression signatures to connect small mole-
cules, genes, and disease. Science 313, 1929–1935.
Lee, S.I., Dudley, A.M., Drubin, D., Silver, P.A., Krogan, N.J., Pe’er, D., and
Koller, D. (2009). Learning a prior on regulatory potential from eQTL data.
PLoS Genet. 5, e1000358.
Leuenroth, S.J., and Crews, C.M. (2008). Triptolide-induced transcriptional
arrest is associated with changes in nuclear substructure. Cancer Res. 68,
5257–5266.
Lin, X., Morgan-Lappe, S., Huang, X., Li, L., Zakula, D.M., Vernetti, L.A., Fesik,
S.W., and Shen, Y. (2007). ‘Seed’ analysis of off-target siRNAs reveals an
essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL
inhibitor ABT-737. Oncogene 26, 3972–3979.
Lindsten, T., Ross, A.J., King, A., Zong, W.X., Rathmell, J.C., Shiels, H.A.,
Ulrich, E., Waymire, K.G., Mahar, P., Frauwirth, K., et al. (2000). The combined
functions of proapoptotic Bcl-2 family members bak and bax are essential for
normal development of multiple tissues. Mol. Cell 6, 1389–1399.
Margolin, A.A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Dalla
Favera, R., and Califano, A. (2006). ARACNE: an algorithm for the reconstruc-
tion of gene regulatory networks in a mammalian cellular context. BMC
Bioinformatics 7 (Suppl 1 ), S7.
Martin, M., Romero, A., Cheang, M.C.U., Lo´pez Garcı´a-Asenjo, J.A., Garcı´a-
Saenz, J.A., Oliva, B., Roma´n, J.M., He, X., Casado, A., de la Torre, J., et al.
(2011). Genomic predictors of response to doxorubicin versus docetaxel in
primary breast cancer. Breast Cancer Res. Treat. 128, 127–136.562 Cancer Cell 21, 547–562, April 17, 2012 ª2012 Elsevier Inc.Me´rino, D., Strasser, A., and Bouillet, P. (2011). Bimmust be able to engage all
pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene,
in press. Published online November 14, 2011. 10.1038/onc.2011.508.
Moffat, J., Grueneberg, D.A., Yang, X., Kim, S.Y., Kloepfer, A.M., Hinkle, G.,
Piqani, B., Eisenhaure, T.M., Luo, B., Grenier, J.K., et al. (2006). A lentiviral
RNAi library for human and mouse genes applied to an arrayed viral high-
content screen. Cell 124, 1283–1298.
Moretti, E., Oakman, C., and Di Leo, A. (2009). Predicting anthracycline
benefit: have we made any progress? Curr. Opin. Oncol. 21, 507–515.
Oltersdorf, T., Elmore, S.W., Shoemaker, A.R., Armstrong, R.C., Augeri, D.J.,
Belli, B.A., Bruncko, M., Deckwerth, T.L., Dinges, J., Hajduk, P.J., et al.
(2005). An inhibitor of Bcl-2 family proteins induces regression of solid
tumours. Nature 435, 677–681.
Peck, D., Crawford, E.D., Ross, K.N., Stegmaier, K., Golub, T.R., and Lamb, J.
(2006). A method for high-throughput gene expression signature analysis.
Genome Biol. 7, R61.
Petros, A.M., Olejniczak, E.T., and Fesik, S.W. (2004). Structural biology of the
Bcl-2 family of proteins. Biochim. Biophys. Acta 1644, 83–94.
Rossi, C., Gasparini, G., Canobbio, L., Galligioni, E., Volpe, R., Candiani, E.,
Toffoli, G., and D’Incalci, M. (1987). Doxorubicin distribution in human breast
cancer. Cancer Treat. Rep. 71, 1221–1226.
Stewart, M.L., Fire, E., Keating, A.E., and Walensky, L.D. (2010). The MCL-1
BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat.
Chem. Biol. 6, 595–601.
Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D., and Liu, L.F. (1984).
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomer-
ase II. Science 226, 466–468.
Titov, D.V., Gilman, B., He, Q.L., Bhat, S., Low, W.K., Dang, Y., Smeaton, M.,
Demain, A.L., Miller, P.S., Kugel, J.F., et al. (2011). XPB, a subunit of TFIIH, is
a target of the natural product triptolide. Nat. Chem. Biol. 7, 182–188.
Tse, C., Shoemaker, A.R., Adickes, J., Anderson, M.G., Chen, J., Jin, S.,
Johnson, E.F., Marsh, K.C., Mitten, M.J., Nimmer, P., et al. (2008). ABT-263: a
potent andorallybioavailableBcl-2 family inhibitor.CancerRes.68, 3421–3428.
van Delft, M.F., Wei, A.H., Mason, K.D., Vandenberg, C.J., Chen, L., Czabotar,
P.E., Willis, S.N., Scott, C.L., Day, C.L., Cory, S., et al. (2006). The BH3mimetic
ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via
Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389–399.
Villunger, A., Michalak, E.M., Coultas, L., Mu¨llauer, F., Bo¨ck, G.,
Ausserlechner, M.J., Adams, J.M., and Strasser, A. (2003). p53- and drug-
induced apoptotic responses mediated by BH3-only proteins puma and
noxa. Science 302, 1036–1038.
Voortman, J., Checinska, A., Giaccone, G., Rodriguez, J.A., and Kruyt, F.A.
(2007). Bortezomib, but not cisplatin, induces mitochondria-dependent
apoptosis accompanied by up-regulation of noxa in the non-small cell lung
cancer cell line NCI-H460. Mol. Cancer Ther. 6, 1046–1053.
Warr, M.R., and Shore, G.C. (2008). Unique biology of Mcl-1: therapeutic
opportunities in cancer. Curr. Mol. Med. 8, 138–147.
Wei, G., Twomey, D., Lamb, J., Schlis, K., Agarwal, J., Stam, R.W., Opferman,
J.T., Sallan, S.E., den Boer, M.L., Pieters, R., et al. (2006). Gene expression-
based chemical genomics identifies rapamycin as a modulator of MCL1 and
glucocorticoid resistance. Cancer Cell 10, 331–342.
Wei, M.C., Zong,W.X., Cheng, E.H., Lindsten, T., Panoutsakopoulou, V., Ross,
A.J., Roth, K.A., MacGregor, G.R., Thompson, C.B., and Korsmeyer, S.J.
(2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial
dysfunction and death. Science 292, 727–730.
Wiegmans, A.P., Alsop, A.E., Bots, M., Cluse, L.A., Williams, S.P., Banks,
K.M., Ralli, R., Scott, C.L., Frenzel, A., Villunger, A., and Johnstone, R.W.
(2011). Deciphering the molecular events necessary for synergistic tumor
cell apoptosis mediated by the histone deacetylase inhibitor vorinostat and
the BH3 mimetic ABT-737. Cancer Res. 71, 3603–3615.
Zhou, P., Levy, N.B., Xie, H., Qian, L., Lee, C.Y., Gascoyne, R.D., and Craig,
R.W. (2001). MCL1 transgenic mice exhibit a high incidence of B-cell
lymphoma manifested as a spectrum of histologic subtypes. Blood 97,
3902–3909.
